These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Clinical development and approval of COVID-19 vaccines. Kalinke U; Barouch DH; Rizzi R; Lagkadinou E; Türeci Ö; Pather S; Neels P Expert Rev Vaccines; 2022 May; 21(5):609-619. PubMed ID: 35157542 [TBL] [Abstract][Full Text] [Related]
25. Profits First, Health Second: The Pharmaceutical Industry and the Global South Comment on "More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry's Role in Widening the Access Gap". Lexchin J Int J Health Policy Manag; 2024; 13():8471. PubMed ID: 39099498 [TBL] [Abstract][Full Text] [Related]
26. The Coming of Age of Nucleic Acid Vaccines during COVID-19. Rando HM; Lordan R; Kolla L; Sell E; Lee AJ; Wellhausen N; Naik A; Kamil JP; ; Gitter A; Greene CS mSystems; 2023 Apr; 8(2):e0092822. PubMed ID: 36861992 [TBL] [Abstract][Full Text] [Related]
27. Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021. COVID-19 National Preparedness Collaborators Lancet; 2022 Apr; 399(10334):1489-1512. PubMed ID: 35120592 [TBL] [Abstract][Full Text] [Related]
28. Allocating a COVID-19 Vaccine: Balancing National and International Responsibilities. Lie RK; Miller FG Milbank Q; 2021 Jun; 99(2):450-466. PubMed ID: 33295679 [TBL] [Abstract][Full Text] [Related]
29. Global COVID-19 Vaccine Inequity: Failures in the First Year of Distribution and Potential Solutions for the Future. Pilkington V; Keestra SM; Hill A Front Public Health; 2022; 10():821117. PubMed ID: 35321196 [TBL] [Abstract][Full Text] [Related]
30. Current and future nanoparticle vaccines for COVID-19. Vu MN; Kelly HG; Kent SJ; Wheatley AK EBioMedicine; 2021 Dec; 74():103699. PubMed ID: 34801965 [TBL] [Abstract][Full Text] [Related]
31. Pandemic preparedness and response: beyond the Access to COVID-19 Tools Accelerator. Saxena A; Baker BK; Banda A; Herlitz A; Miller J; Karrar K; Fleurbaey M; Chiwa E; Atuire CA; Hirose I; Hassoun N BMJ Glob Health; 2023 Jan; 8(1):. PubMed ID: 36650015 [TBL] [Abstract][Full Text] [Related]
32. Recalling the universal health coverage vision and equity in the COVID-19 vaccine distribution plan. Adejumo OA; Adejumo OA Pan Afr Med J; 2021; 39():197. PubMed ID: 34603578 [TBL] [Abstract][Full Text] [Related]
33. Which roads lead to access? A global landscape of six COVID-19 vaccine innovation models. Alonso Ruiz A; Bezruki A; Shinabargar E; Large K; Vieira M; Slovenski I; Liu Y; Agarwal S; Becker A; Moon S Global Health; 2024 Mar; 20(1):25. PubMed ID: 38532484 [TBL] [Abstract][Full Text] [Related]
34. Public health and social measures to mitigate the health and economic impact of the COVID-19 pandemic in Turkey, Egypt, Ukraine, Kazakhstan, and Poland during 2020-2021: situational analysis. Kitamura N; Abbas K; Nathwani D BMC Public Health; 2022 May; 22(1):991. PubMed ID: 35578330 [TBL] [Abstract][Full Text] [Related]
35. Innovative vaccine approaches-a Keystone Symposia report. Cable J; Rappuoli R; Klemm EJ; Kang G; Mutreja A; Wright GJ; Pizza M; Castro SA; Hoffmann JP; Alter G; Carfi A; Pollard AJ; Krammer F; Gupta RK; Wagner CE; Machado V; Modjarrad K; Corey L; B Gilbert P; Dougan G; Lurie N; Bjorkman PJ; Chiu C; Nemes E; Gordon SB; Steer AC; Rudel T; Blish CA; Sandberg JT; Brennan K; Klugman KP; Stuart LM; Madhi SA; Karp CL Ann N Y Acad Sci; 2022 May; 1511(1):59-86. PubMed ID: 35029310 [TBL] [Abstract][Full Text] [Related]
36. COVID-19 vaccines and treatments nationalism: Challenges for low-income countries and the attainment of the SDGs. Nhamo G; Chikodzi D; Kunene HP; Mashula N Glob Public Health; 2021 Mar; 16(3):319-339. PubMed ID: 33317389 [TBL] [Abstract][Full Text] [Related]
37. The health economic-industrial complex: production and innovation for universal health access, Brazil. Gadelha CA; Maretto G; Nascimento MA; Kamia F Bull World Health Organ; 2024 May; 102(5):352-356. PubMed ID: 38680461 [TBL] [Abstract][Full Text] [Related]
38. [Dilemma, causes and countermeasures of global health governance: taking COVID-19 Vaccines Global Access Facility as an example]. Bai AY; Zhang B; Jiang Y; Qiao Y Zhonghua Liu Xing Bing Xue Za Zhi; 2022 Apr; 43(4):483-487. PubMed ID: 35443301 [TBL] [Abstract][Full Text] [Related]